Effects of Whole-Body Vibration on Heart Rate Variability During Post-Exercise Recovery
NCT07932431, Not applicable, Not yet recruiting, Hamza Budak
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of Whole-Body Vibration on Heart Rate Variability During Post-Exercise Recovery | ClinicalTrials.gov |
| NCT number | NCT07932431 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 10 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Hamza Budak | ClinicalTrials.gov |
| Conditions | Autonomic Nervous System Activity | ClinicalTrials.gov |
| Interventions | Whole-Body Vibration (WBV), Passive Recovery | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Very Low Frequency (VLF) Power | During the exercise test and the subsequent 15-minute recovery period in each experimental session. | Very low frequency (VLF) power is a frequency-domain parameter of heart rate variability (HRV), expressed in ms². HRV will be continuously recorded using a Polar H10 chest strap during the entire exercise test and the 15-minute recovery period. VLF power will be analyzed using Kubios HRV software to assess autonomic responses under whole-body vibration and passive recovery conditions. | ClinicalTrials.gov |
| Primary | Low Frequency (LF) Power | During the exercise test and the subsequent 15-minute recovery period in each experimental session. | Low frequency (LF) power is a frequency-domain parameter of heart rate variability (HRV), expressed in ms². HRV will be continuously recorded using a Polar H10 chest strap during the entire exercise test and the 15-minute recovery period. LF power will be analyzed using Kubios HRV software to evaluate autonomic responses under whole-body vibration and passive recovery conditions. | ClinicalTrials.gov |
| Primary | High Frequency (HF) Power | During the exercise test and the subsequent 15-minute recovery period in each experimental session. | High frequency (HF) power is a frequency-domain parameter of heart rate variability (HRV), expressed in ms², and is commonly used as an indicator of cardiac parasympathetic modulation. HRV will be continuously recorded using a Polar H10 chest strap during the entire exercise test and the 15-minute recovery period. HF power will be analyzed using Kubios HRV software to compare responses between whole-body vibration and passive recovery conditions. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)